CN112557543A - Method for measuring rivaroxaban and related substances thereof - Google Patents

Method for measuring rivaroxaban and related substances thereof Download PDF

Info

Publication number
CN112557543A
CN112557543A CN202011427144.7A CN202011427144A CN112557543A CN 112557543 A CN112557543 A CN 112557543A CN 202011427144 A CN202011427144 A CN 202011427144A CN 112557543 A CN112557543 A CN 112557543A
Authority
CN
China
Prior art keywords
rivaroxaban
mobile phase
related substances
substances according
high performance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202011427144.7A
Other languages
Chinese (zh)
Other versions
CN112557543B (en
Inventor
张晓飞
黄乐群
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Jiayi Medicine Co ltd
Original Assignee
Jiangsu Jiayi Medicine Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Jiayi Medicine Co ltd filed Critical Jiangsu Jiayi Medicine Co ltd
Priority to CN202011427144.7A priority Critical patent/CN112557543B/en
Publication of CN112557543A publication Critical patent/CN112557543A/en
Application granted granted Critical
Publication of CN112557543B publication Critical patent/CN112557543B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

The invention provides a method for measuring rivaroxaban and related substances thereof, which comprises the steps of adopting a high performance liquid chromatography to measure, dissolving rivaroxaban in a diluent to obtain a sample solution, injecting the sample solution into a high performance liquid chromatograph with a core-shell chromatographic column as a stationary phase, adopting a flow without an ion pair reagent to carry out gradient elution relative to the sample solution, separating to obtain an eluent, and injecting the eluent into a detector to measure. The invention adopts the core-shell chromatographic column, has good column efficiency and can bring good peak shape and separation; meanwhile, the mobile phase does not contain an ion pair reagent, so that various ghost peaks generated in the analysis process are avoided, the interference of a base line is effectively reduced, the sensitivity of impurity detection is greatly improved, various processes and degradation impurities in rivaroxaban can be simultaneously separated, and the method has important significance for impurity control and product safety procedures in rivaroxaban bulk drugs.

Description

Method for measuring rivaroxaban and related substances thereof
Technical Field
The invention relates to a method for determining rivaroxaban and related substances thereof, and belongs to the technical field of medical chemical analysis.
Background
Rivaroxaban is an oral anticoagulant with high selectivity and capable of directly inhibiting blood coagulation factor Xa, and the molecular formula of rivaroxaban is C19H18ClN3O5S, the chemical name is: 5-chloro-N- ({ (5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) -phenyl]-1, 3-oxazolidin-5-yl } -methyl) -2-thiophene-carboxamide having the formula:
Figure BDA0002825409620000011
in the chemical synthesis process of rivaroxaban, various intermediates, side reaction impurities and degradation products are inevitably contained in the raw material medicine due to the residue of the starting raw material intermediate and the occurrence of chemical reaction side reactions. In order to ensure the quality of rivaroxaban bulk drug, a scientific analysis method is needed to detect and control various impurities in the rivaroxaban bulk drug.
Related quality standards for controlling the rivaroxaban impurities are not yet collected by U.S. pharmacopoeia, European pharmacopoeia, Chinese pharmacopoeia and other authoritative Wei pharmacopoeias, and an authoritative method which can be referred to in the current industry is a related substance method collected in the standard of entry registration of rivaroxaban preparations.
The invention patent CN107941936B discloses a method for separating and measuring rivaroxaban and impurities thereof and application thereof, wherein in the method, an impurity in front of a main peak cannot be completely separated from the main peak, and the separation degree of the main peak and the impurities cannot be ensured to meet the requirement under the condition similar to shoulder seam.
The invention patent CN105004802B discloses a method for separating and measuring rivaroxaban and related impurities thereof by using a liquid chromatography, wherein an ion pair is added into a mobile phase A, the time required for balance is long, the ion pair reagent is unstable, a base line has a plurality of unknown small peaks, the measurement of related substances is greatly interfered, and ghost peak small columns cannot be added for removal; and ions can cause irreversible damage to the chromatographic column to affect the active sites on the stationary phase of the chromatographic column, thereby not only affecting the reproducibility and durability of the method, but also greatly shortening the service life of the chromatographic column.
The invention patent CN2019104208181A discloses a method for detecting related substances of rivaroxaban and a preparation thereof, wherein the method has the advantages that although a plurality of impurities are well separated, the analysis time of the analysis method is long, the total operation time reaches 70 minutes, the peak-off time of the final impurities is 58 minutes, the analysis time is prolonged to improve the separation degree, the column efficiency of partial chromatographic peaks is reduced, the analysis efficiency is low, the cost control on the production angle is very unfavorable, and the waste liquid generated by the operation for a long time brings the cost of waste liquid treatment.
Based on the above reasons, in the prior art, methods used for separation and detection of rivaroxaban and related substances thereof have the problems of interference peak influence, poor durability, poor reproducibility, low detection sensitivity, manual blank solvent deduction in the calculation process and the like, and have great influence on calculation and judgment of detection results.
Disclosure of Invention
The invention aims to provide a method for measuring rivaroxaban and related substances thereof, which does not contain ion pairs, uses a core-shell chromatographic column, can separate more impurities and solves the problem of poor separation of impurity peaks close to a main peak and the main peak. The method has the advantages of simple steps, high sensitivity, good durability, good reproducibility, high accuracy of the measurement result and high separation speed,
the technical solution of the invention is as follows: a method for measuring rivaroxaban and related substances thereof specifically comprises the following steps:
1) dissolving rivaroxaban in a diluent to obtain a sample solution;
2) preparing a mobile phase A and a mobile phase B;
3) performing determination by adopting a high performance liquid chromatography, injecting the sample solution prepared in the step 1) into a high performance liquid chromatograph, performing gradient elution on the sample solution by adopting the mobile phase A and the mobile phase B prepared in the step 2), and separating to obtain an eluent;
4) the eluent is injected into a detector for measurement.
The diluent in the step 1) is acetonitrile-water solution, wherein the acetonitrile: the volume ratio of the water is 60: 30-80: 20.
The flow rate of the mobile phase in the step 3) is 0.8-1.5ml/min, and preferably 1.2 ml/min.
The volume ratio of the mobile phase A to the mobile phase B in the step 3) is (5-95): 95-5 (the sum of the volume ratios of the mobile phase A to the mobile phase B is 100), and the specific process of the gradient elution is shown in the following table 1:
Figure BDA0002825409620000031
TABLE 1
The high performance liquid chromatography comprises the following conditions:
firstly, the stationary phase is a core-shell chromatographic column of octadecylsilane chemically bonded silica;
further, the chromatographic column is a core-shell type C18 chromatographic column, preferably, the chromatographic column is an Agilent poroshell EC-C18 column which adopts a special core-shell type structure and provides different chromatographic selectivity from a conventional end-capped chromatographic column.
Further, the temperature of the chromatographic column in a box is 40-60 ℃, and preferably 50 ℃. High column temperatures can provide better column efficiency and separation within the tolerable range of the chromatography column.
② the mobile phase A is a mixed solvent of buffer saline solution and methanol, and does not contain ion pair reagent. The mass ratio of the buffer saline solution to the methanol in the mixed solvent is 100: 0-85: 15.
Further, the buffer salt in the buffer saline solution is an alkali metal phosphate salt including a sodium phosphate salt or a potassium phosphate salt, preferably one or more of dipotassium hydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate, and more preferably potassium dihydrogen phosphate or sodium dihydrogen phosphate. The concentration of the buffer salt in the buffer salt water solution is 1-50 mmol/L, preferably 5-20 mmol/L.
Furthermore, 100-500 mul of phosphoric acid, preferably 150-250 mul of phosphoric acid is also added into the buffer saline solution.
③ the mobile phase B is a ternary mixed solvent of water, acetonitrile and methanol; acetonitrile: methanol: the volume ratio of water is 10:0: 0-4: 4:2, preferably 6:2:2 or 5:3:2 or 4:4:2, and more preferably 5:3: 2.
And fourthly, the detector is an ultraviolet detector, and the wavelength of ultraviolet rays is 240-260 nm, preferably 250 nm.
The related substances comprise process impurities and degradation impurities, and specifically comprise one or more of impurities A, B, C, D, E, F, G, H, I, J, K, M, N, O and P, and the structural formula of each impurity is specifically as follows:
Figure DEST_PATH_IMAGE001
Figure BDA0002825409620000051
compared with the prior art, the invention has the advantages that:
1) the core-shell chromatographic column is adopted, so that the column efficiency is good, and good peak type and separation can be brought;
2) the mobile phase does not contain ion pair reagents, so that various ghost peaks generated in the analysis process are avoided, ghost peak trapping small columns can be applied, the interference of a base line is effectively reduced, and the sensitivity of impurity detection is greatly improved;
3) 15 known processes and degradation impurities in rivaroxaban can be separated simultaneously, two unknown impurities (wrapped in the main peak and not separated in the embodiment 6) with the same polarity as the main peak before and after the main peak can be separated, and the separation quantity and the detection precision are greatly improved compared with the prior art;
4) when more impurities are separated, the analysis time is short, the peak emergence time of the impurities with the minimum polarity is 35min, and the time efficiency is improved higher compared with the peak emergence time near 58min in other patents.
5) The method is simple, convenient and feasible, high in sensitivity, high in accuracy and good in reproducibility, can be used for quickly and effectively separating and determining the content of each related substance in rivaroxaban API, and has important significance on impurity control and product safety procedures in rivaroxaban bulk drugs.
Drawings
FIG. 1 is a high performance liquid chromatogram of the blank diluent of example 1.
FIG. 2 is a high performance liquid chromatogram of a rivaroxaban mixed impurities solution of example 1.
FIG. 3 is a high performance liquid chromatogram of a 0.1% rivaroxaban self-control solution of example 1.
FIG. 4 is a high performance liquid chromatogram of a rivaroxaban test solution of example 1.
FIG. 5 is a high performance liquid chromatogram of the blank diluent of example 2.
FIG. 6 is a high performance liquid chromatogram of a rivaroxaban mixed impurities solution of example 2.
FIG. 7 is a high performance liquid chromatogram of the blank diluent of example 3.
FIG. 8 is a high performance liquid chromatogram of a rivaroxaban mixed impurities solution of example 3.
FIG. 9 is a high performance liquid chromatogram of the blank diluent of example 4.
FIG. 10 is a high performance liquid chromatogram of a rivaroxaban mixed impurities solution of example 4.
FIG. 11 is a high performance liquid chromatogram of the blank diluent of example 5.
FIG. 12 is a high performance liquid chromatogram of a rivaroxaban mixed impurities solution of example 5.
FIG. 13 is a high performance liquid chromatogram of a blank solvent of example 6.
FIG. 14 is a high performance liquid chromatogram of a sample solution of rivaroxaban from example 6.
Detailed Description
The technical scheme of the invention is further illustrated by the following examples. The technical solutions and related parameter settings given in the embodiments are exemplary and are intended to be used for explaining the present invention, and should not be construed as limiting the present invention.
Example 1
The method for separating and determining rivaroxaban and impurities thereof specifically comprises the following steps:
1) apparatus and conditions
The instrument comprises the following steps: a high performance liquid chromatograph; a chromatographic column: a core-shell chromatographic column using octadecylsilane chemically bonded silica as a filler, wherein the type of the chromatographic column is Agilent Poroshell 120EC-C18, 150 x 4.6mm, 2.7 mu m or a chromatographic column with equivalent performance; the detector detects the wavelength: 250 nm; flow rate of mobile phase: 1.2 ml/min; mobile phase A: using 10mmol/mL potassium dihydrogen phosphate buffer solution (1.36g potassium dihydrogen phosphate with 1000mL water, adding 200. mu.l phosphoric acid) -methanol (95:5) as mobile phase A; mobile phase B: acetonitrile-methanol-water (50:30:20) as mobile phase B; diluent agent: acetonitrile-water (70: 30); the column temperature of the chromatographic column is 50 ℃; the elution gradient is shown in table 2 below:
Figure BDA0002825409620000061
TABLE 2
Sample introduction amount: 5 μ l.
2) Experimental procedure
(1) Preparing a mixed impurity solution: taking an appropriate amount of each of impurity A, impurity B, impurity C, impurity D, impurity E, impurity F, impurity G, impurity H, impurity I, impurity J, impurity K, impurity L, impurity M, impurity N, impurity O and rivaroxaban, and diluting with a solvent to prepare a mixed impurity solution containing 0.4mg of rivaroxaban and 0.4 mu G of each impurity per 1 ml;
(2) preparing a test solution: dissolving the product with solvent [ acetonitrile-water (70:30) ] under ultrasound, cooling to room temperature, and diluting with solvent to obtain solution containing 0.4mg per 1ml as test solution;
(3) preparing a control solution: precisely measuring 1ml of a sample solution, placing the sample solution in a 100ml measuring flask, diluting the sample solution to a scale with a solvent [ acetonitrile-water (70:30) ], and shaking up; precisely measuring 1ml of the solution, placing the solution in a 10ml measuring flask, diluting the solution to a scale with a mobile phase, and shaking up to obtain a control solution;
(4) injecting 5 μ l of each of the above diluent, system suitability test solution, sample solution and control solution into high performance liquid chromatograph, measuring according to the above chromatographic conditions, performing linear gradient elution according to data shown in Table 1, and recording chromatogram, wherein the results are shown in FIGS. 1-5.
3) The results of the experiment are shown in table 3 below:
Figure BDA0002825409620000071
Figure BDA0002825409620000081
TABLE 3
As a result: the components can be separated from each other at a base line, the separation requirement of pharmacopeia is met, the blank solvent does not interfere the detection of each component, the signal-to-noise ratio of 0.1 percent of the self-contrast peak is good, and the detection sensitivity is high. (as shown in FIGS. 1-4 and Table 3).
Example 2
1) The flow rate was adjusted to 1.0ml/min based on example 1
2) The results of the experiment are shown in table 4 below:
Figure BDA0002825409620000082
Figure BDA0002825409620000091
TABLE 4
As a result: baseline separation between each component was achieved, pharmacopeia separation requirements were met, and blank solvent did not interfere with the detection of each component (as shown in figures 5-6 and table 4).
Example 3
1) The flow rate was adjusted to 1.4ml/min on the basis of example 1
2) The results of the experiment are shown in table 5 below:
Figure BDA0002825409620000092
TABLE 5
As a result: the components can be separated from each other at a baseline, the separation requirement of pharmacopeia is met, and the blank solvent does not interfere the detection of the components. (as shown in figures 7-8 and table 5).
Example 4
1) The column temperature was adjusted to 55 ℃ based on example 1
2) The results of the experiment are shown in table 6 below:
Figure BDA0002825409620000101
TABLE 6
As a result: all the other components except the impurities G and H can be separated at a base line, the separation requirement of pharmacopeia is met, and the blank solvent does not interfere the detection of all the components. (as shown in FIGS. 9-10 and Table 6).
Example 5
1) The column temperature was adjusted to 45 ℃ based on example 1
2) The results of the experiment are shown in table 7 below:
Figure BDA0002825409620000111
TABLE 7
As a result: the components can be separated from each other at a baseline, the separation requirement of pharmacopeia is met, and the blank solvent does not interfere the detection of the components. (as shown in FIGS. 11-12 and Table 7).
Example 6
The method for separating and determining rivaroxaban and impurities thereof specifically comprises the following steps:
1) apparatus and conditions
High performance liquid chromatograph: shimadzu LC-2010C; a chromatographic column: purospher Star RP-18 (55X 4mm, 3 μm); the detector detects the wavelength: 250 nm; sample introduction amount: 5 mu l of the solution; diluent agent: diluent agent: acetonitrile-0.01 mol/L phosphoric acid solution (6.7 ml of 11.5g or 85% phosphoric acid, diluted to 10.0L with water) ═ 3: 2;
2) experimental procedure
(1) Preparing a mixed impurity solution: taking an appropriate amount of each of impurity A, impurity B, impurity C, impurity D, impurity E, impurity F, impurity G, impurity H, impurity I, impurity J, impurity K, impurity L, impurity M, impurity N, impurity O and rivaroxaban, and diluting with a solvent to prepare a mixed impurity solution containing 0.4mg of rivaroxaban and 0.4 mu G of each impurity per 1 ml;
(2) preparing a mobile phase A: adding 0.1% phosphoric acid into 1000ml of water, and mixing uniformly; the mobile phase B is acetonitrile;
(3) and (2) injecting 10 mu l of diluent and the sample solution obtained in the step (1) into a high performance liquid chromatograph, wherein the model of a chromatographic column is Purospher Star RP-18, the flow rate of a mobile phase is set to be 1.0ml/min, the detection wavelength is 250nm, and the temperature of a chromatographic column box is 45 ℃. The elution gradient is shown in table 4 below:
Figure BDA0002825409620000121
TABLE 4
And (5) carrying out linear gradient elution according to the data shown in the table 4 to complete the separation and determination of related substances of rivaroxaban. Recording chromatogram, high performance liquid chromatogram is shown in FIGS. 6-7. Under the condition, compared with example 1, rivaroxaban and impurity peaks only have 12 peaks, and a plurality of impurity peaks cannot be separated and overlapped or have poor separation degree.
Compared with the method in the embodiment 2 (the existing method), the method in the embodiment 1 has the advantages that the number of separable impurities is large, the separation degree is good, and therefore the content of each related substance in rivaroxaban API can be effectively separated and determined, so that the quality of rivaroxaban bulk drugs and preparations thereof is controllable, and the safety and effectiveness of products are finally determined.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention should be equivalent or changed within the scope of the present invention.

Claims (10)

1. A method for measuring rivaroxaban and related substances thereof specifically comprises the following steps:
1) dissolving rivaroxaban in a diluent to obtain a sample solution;
2) preparing a mobile phase A and a mobile phase B;
3) performing determination by adopting a high performance liquid chromatography, injecting the sample solution prepared in the step 1) into a high performance liquid chromatograph, performing gradient elution on the sample solution by adopting the mobile phase A and the mobile phase B prepared in the step 2), and separating to obtain an eluent;
4) injecting the eluent obtained in the step 3) into a detector for measurement;
the method is characterized in that: the stationary phase in the high performance liquid chromatograph is a core-shell chromatographic column of octadecylsilane chemically bonded silica; the mobile phase A is a mixed solvent of a buffered saline solution and methanol, and the buffered saline solution does not contain an ion-pairing agent.
2. The method for determining rivaroxaban and related substances according to claim 1, wherein: the temperature of the chromatographic column in the column box is 40-60 ℃.
3. The method for determining rivaroxaban and related substances according to claim 1, wherein: the mass ratio of the buffer saline solution to the methanol in the mobile phase A is 100: 0-85: 15.
4. The method for determining rivaroxaban and related substances according to claim 3, wherein: the buffer salt in the buffer saline solution is alkali metal phosphate, including sodium phosphate or potassium phosphate, specifically including one or more of dipotassium hydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate and sodium dihydrogen phosphate.
5. The method for determining rivaroxaban and related substances according to claim 4, wherein: the concentration of the buffer salt in the buffer salt water solution is 1-50 mmol/L.
6. The method for determining rivaroxaban and related substances according to claim 4, wherein: and adding 100-500 mu l of phosphoric acid into the buffer saline solution.
7. The method for determining rivaroxaban and related substances according to claim 1, wherein: the mobile phase B is a ternary mixed solvent of water, acetonitrile and methanol; wherein acetonitrile: methanol: the volume ratio of water is 10:0: 0-4: 4: 2.
8. The method for determining rivaroxaban and related substances according to claim 1, wherein: the detector is an ultraviolet detector, and the ultraviolet wavelength of the ultraviolet detector is 240-260 nm.
9. The method for determining rivaroxaban and related substances according to claim 1, wherein: the volume ratio of the mobile phase A to the mobile phase B in the step 3) is (5-95) - (95-5), and the sum of the volume ratios of the mobile phase A to the mobile phase B is 100; the flow rate of the mobile phase is 0.8-1.5 ml/min.
10. The method for determining rivaroxaban and related substances according to claim 1, wherein: the diluent in the step 1) is acetonitrile-water solution, wherein the acetonitrile: the volume ratio of the water is 60: 30-80: 20.
CN202011427144.7A 2020-12-09 2020-12-09 Method for determining rivaroxaban and related substances thereof Active CN112557543B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011427144.7A CN112557543B (en) 2020-12-09 2020-12-09 Method for determining rivaroxaban and related substances thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011427144.7A CN112557543B (en) 2020-12-09 2020-12-09 Method for determining rivaroxaban and related substances thereof

Publications (2)

Publication Number Publication Date
CN112557543A true CN112557543A (en) 2021-03-26
CN112557543B CN112557543B (en) 2022-11-22

Family

ID=75060784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011427144.7A Active CN112557543B (en) 2020-12-09 2020-12-09 Method for determining rivaroxaban and related substances thereof

Country Status (1)

Country Link
CN (1) CN112557543B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114280174A (en) * 2021-12-07 2022-04-05 嘉实（湖南）医药科技有限公司 Detection method of avanafil and related impurities thereof
CN116500173A (en) * 2023-07-03 2023-07-28 则正(上海)生物科技有限公司 Method for determining impurity content in rivaroxaban drug

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106432218A (en) * 2015-12-18 2017-02-22 重庆植恩药业有限公司 Rivaroxaban impurities and preparing method and application thereof
CN107941936A (en) * 2017-11-17 2018-04-20 重庆华邦制药有限公司 The method and application of separation determination razaxaban and its impurity
CN110057942A (en) * 2019-05-20 2019-07-26 海南皇隆制药股份有限公司 A kind of detection method of the related substance of razaxaban and its preparation
CN110954603A (en) * 2018-09-27 2020-04-03 辽宁远大诺康生物制药有限公司 Method for determining rivaroxaban and related substances thereof by using high performance liquid chromatography
CN111579685A (en) * 2020-05-29 2020-08-25 南京品生医疗科技有限公司 Kit for detecting anticoagulant drugs in blood plasma and application thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106432218A (en) * 2015-12-18 2017-02-22 重庆植恩药业有限公司 Rivaroxaban impurities and preparing method and application thereof
CN107941936A (en) * 2017-11-17 2018-04-20 重庆华邦制药有限公司 The method and application of separation determination razaxaban and its impurity
CN110954603A (en) * 2018-09-27 2020-04-03 辽宁远大诺康生物制药有限公司 Method for determining rivaroxaban and related substances thereof by using high performance liquid chromatography
CN110057942A (en) * 2019-05-20 2019-07-26 海南皇隆制药股份有限公司 A kind of detection method of the related substance of razaxaban and its preparation
CN111579685A (en) * 2020-05-29 2020-08-25 南京品生医疗科技有限公司 Kit for detecting anticoagulant drugs in blood plasma and application thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114280174A (en) * 2021-12-07 2022-04-05 嘉实（湖南）医药科技有限公司 Detection method of avanafil and related impurities thereof
CN114280174B (en) * 2021-12-07 2023-12-29 嘉实（湖南）医药科技有限公司 Detection method of avanafil and related impurities thereof
CN116500173A (en) * 2023-07-03 2023-07-28 则正(上海)生物科技有限公司 Method for determining impurity content in rivaroxaban drug

Also Published As

Publication number Publication date
CN112557543B (en) 2022-11-22

Similar Documents

Publication Publication Date Title
CN107941936B (en) Method for separating and determining rivaroxaban and impurities thereof and application
CN112557543B (en) Method for determining rivaroxaban and related substances thereof
CN101762647B (en) Method for measuring 2-furfural in beer by using high performance liquid chromatography
CN106855545A (en) Liposoluble vitamin simultaneously in detection feed and the method for water soluble vitamin
CN108061767B (en) Method for separating and measuring rivaroxaban intermediate and related impurities thereof by HP L C method
CN104678026B (en) Method for determining content of tetrabutylammonium bromide in organic medicine
CN104280495B (en) Detect the method for the jinggangmycin A in water and rice plant
CN113092639A (en) Method for detecting content of rivaroxaban related substances by ultra-performance liquid chromatography-mass spectrometry
CN104914194B (en) A method of with Determination of menthol in gas chromatograph detection Dementholized mint oil dripping pill
CN114354801B (en) Analysis method for contents of three aminopyridine isomers in (R) -3-Boc-aminopiperidine
CN110954629A (en) Control method for measuring content of furfuryl amine in furosemide
CN104502486B (en) A kind of apply the method for methyl vanillin and ethyl vanillin in Headspace-solid phase microextraction technical measurement milk powder
CN106483202A (en) A kind of separation and the method measuring alitretinoin and isomer
CN110095554B (en) Method for analyzing milrinone related substances by high performance liquid chromatography
CN114280191A (en) Method for detecting related substances in bis-cysteine and preparation thereof
CN110412164B (en) Method for detecting related substances of mexiletine hydrochloride
CN114200062A (en) Method for detecting tetraethylene glycol dimethyl ether in leather
CN113820417A (en) Method for separating and measuring piroxicam and impurities thereof
CN107807182B (en) Method for measuring content of ganoderic acid A in ganoderma lucidum syrup
CN109085255B (en) Method for analyzing and preparing 3- (N-p-toluenesulfonyl-L-alanyloxy) -5-phenylpyrrole and enantiomer thereof by using HPLC method
CN103869026B (en) The preprocess method of mulberry leaf compound preparation and the detection method of 1-DNJ
CN111812253A (en) Method for detecting potential genotoxic impurities in compound containing benzimidazole structure
CN111983108A (en) Chiral analysis method for main alkaloids in electronic smoke sol
CN114740105B (en) Liquid chromatographic separation detection method for proline and N-methyl proline and application thereof
CN112213411B (en) Method for detecting genotoxic impurities in diacerein

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A method for determining rivaroxaban and its related substances

Granted publication date: 20221122

Pledgee: Bank of China Limited by Share Ltd. Nantong economic and Technological Development Zone sub branch

Pledgor: JIANGSU SINOBIOPHARMA Co.,Ltd.

Registration number: Y2024980030145